FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
--------------	--

hours per response:

3235-0287 OMB Number: Estimated average burden

0.5

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Plooster Matthew R						2. Issuer Name and Ticker or Trading Symbol KEMPHARM, INC [KMPH]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
	IPHARM,		(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 04/21/2015								Officer (give title Other (specify below) below)					
2656 CR0	OSSPARK :	ROAD, SUITE	100		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								ndividual or Jo	int/Grou	up Filing ((Check A	pplicable	
(Street)	'ILLE IA	L.	52241										Line	X Form file	-	ne Repor ore than	-		
(City)	(St	tate)	(Zip)																
		Ta	ıble I - N	on-Deri	ivati	ve S	ecur	ities Ac	quire	d, Di	sposed of	, or Ben	eficially	/ Owned					
1. Title of S	ecurity (Inst	r. 3)		2. Transa Date (Month/D		ar) E	f any	emed ion Date, /Day/Year)	3. Transa Code (8)		4. Securities Disposed Of			5. Amount o Securities Beneficially Owned Follo Reported		6. Owner Form: Di (D) or Inc (I) (Instr.	irect direct 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code V		Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common	Stock			04/21	/201	5			С		4,545(1)	A	(4)	4,545	5	D)		
Common Stock			04/21	/201	2015					1,117 ⁽²⁾	A	(4)	1,117		A Cl In Cl I FF M Ry Pl Rc		By TD Ameritrade Clearing Inc. Custodian FBO Matthew Ryan Plooster Roth IRA, as trustee		
Common	Common Stock			04/21/2015		5			С		428,304 ⁽³⁾) A	(4)	428,30	304 I			By Bridgepoint Investment Partners I LLLP ⁽⁵⁾	
			Table II								osed of,			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8)		5. N Deri Sec Acq or D	umber of vative urities uired (A) visposed of (Instr. 3, 4	6. Dat		cisable and	7. Title and Amour of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Owners Form: Direct (I or Indire (I) (Instr	Beneficial Ownership ect (Instr. 4)			
									Date		Expiration		Amount or Number]	(Instr.				
				(Code	v	(A)	(D)		isable	Date	Title	of Shares						
Series C Convertible Preferred Stock	(4)	04/21/2015			С			25,642	(4	4)	(4)	Common Stock	3,418	\$0.00		0	D		
Series D Convertible Preferred Stock	(4)	04/21/2015			С			8,456	(4	4)	(4)	Common Stock	1,127	\$0.00		0	D		
Series C Convertible Preferred Stock	(4)	04/21/2015			С			8,381	(4	4)	(4)	Common Stock	1,117	\$0.00		0	I	By TD Ameritrade Clearing Inc. Custodian FBO Matthew Ryan Plooster Roth IRA, as trustee	
Series A Convertible Preferred Stock	(4)	04/21/2015			С			1,701,011	(4	4)	(4)	Common Stock	226,801	\$0.00		0	I	By Bridgepoint Investment Partners I LLLP ⁽⁵⁾	

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) S. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Day/ (Month/Day/)	ate	7. Title and of Securit Underlying Derivative (Instr. 3 and	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Series B Convertible Preferred Stock	(4)	04/21/2015		С			1,511,279	(4)	(4)	Common Stock	201,503	\$0.00	0	I	By Bridgepoint Investment Partners I LLLP ⁽⁵⁾
Warrant to Purchase Series D Preferred Stock (right to buy)	(4)	04/21/2015		С			384	(4)	(4)	Common Stock	51	\$0.78	0	D	
Warrant to Purchase Common Stock (right to buy)	\$5.85	04/21/2015		C ⁽⁶⁾		51		(6)	(7)	Common Stock	51	\$0.00	51	D	

Explanation of Responses:

- 1. The total represents shares received upon conversion of Series C and Series D convertible preferred stock.
- $2. \ The \ total \ represents \ shares \ received \ upon \ conversion \ of \ Series \ C \ convertible \ preferred \ stock.$
- 3. The total represents shares received upon conversion of Series A and Series B convertible preferred stock.
- 4. Effective upon the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B, Series C and Series D convertible preferred stock automatically converted into 0.13333 shares of common stock. The convertible preferred stock had no expiration date.
- 5. The shares directly held by Bridgepoint Investment Partners I LLLP, or Bridgepoint, are indirectly held by its general partner, Bridgepoint Capital Partners, LLP, or BPCP. The individual managers of BPCP are Matthew R. Plooster and Adam S. Claypool. Matthew R. Plooster and Adam S. Claypool share voting and dispositive power with regard to the shares directly held by Bridgepoint.
- 6. Represents a warrant to purchase shares of common stock of the Issuer following the conversion of the Series D convertible preferred stock on a 1-for-0.13333 share basis. The number of shares and price per share reported herein reflects such conversion. The warrant is immediately exercisable at any time at the option of the holder.
- 7. The warrant expires as of 5:00 p.m. C.S.T. on the earliest of (i) June 2, 2019 and (ii) the effective date of the closing of a Company Sale Transaction (as such term is defined in the warrant).

Remarks:

/s/ James C.T. Linfield, Attorney-in-Fact 04/21/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

 $Persons \ who \ respond \ to \ the \ collection \ of \ information \ contained \ in \ this \ form \ are \ not \ required \ to \ respond \ unless \ the \ form \ displays \ a \ currently \ valid \ OMB \ Number.$